BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 29129044)

  • 1. Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth.
    Lee J; Shin YJ; Lee K; Cho HJ; Sa JK; Lee SY; Kim SH; Lee J; Yoon Y; Nam DH
    Cancer Res Treat; 2018 Jul; 50(3):1009-1022. PubMed ID: 29129044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas.
    Higgins DMO; Caliva M; Schroeder M; Carlson B; Upadhyayula PS; Milligan BD; Cheshier SH; Weissman IL; Sarkaria JN; Meyer FB; Henley JR
    BMC Cancer; 2020 Dec; 20(1):1213. PubMed ID: 33302912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
    Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
    PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interference with PSMB4 Expression Exerts an Anti-Tumor Effect by Decreasing the Invasion and Proliferation of Human Glioblastoma Cells.
    Cheng YC; Tsai WC; Sung YC; Chang HH; Chen Y
    Cell Physiol Biochem; 2018; 45(2):819-831. PubMed ID: 29414809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, Biodistribution, and Toxicity Evaluation of Anti-SEMA3A (F11) in
    Lee J; Kim D; Son E; Yoo SJ; Sa JK; Shin YJ; Yoon Y; Nam DH
    Anticancer Res; 2018 May; 38(5):2803-2810. PubMed ID: 29715102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autocrine semaphorin 3A signaling promotes glioblastoma dispersal.
    Bagci T; Wu JK; Pfannl R; Ilag LL; Jay DG
    Oncogene; 2009 Oct; 28(40):3537-50. PubMed ID: 19684614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
    Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
    J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression.
    Tseng JH; Chen CY; Chen PC; Hsiao SH; Fan CC; Liang YC; Chen CP
    Oncotarget; 2017 Feb; 8(9):14666-14679. PubMed ID: 28108734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
    Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
    Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel role of semaphorin 3A in the growth and progression of hepatocellular carcinoma.
    Li X; Chen Q; Yin D; Shi S; Yu L; Zhou S; Chen E; Zhou Z; Shi Y; Fan J; Zhou J; Dai Z
    Oncol Rep; 2017 Jun; 37(6):3313-3320. PubMed ID: 28498470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZWINT: A potential therapeutic biomarker in patients with glioblastoma correlates with cell proliferation and invasion.
    Yang L; Han N; Zhang X; Zhou Y; Chen R; Zhang M
    Oncol Rep; 2020 Jun; 43(6):1831-1844. PubMed ID: 32323832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
    Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P
    Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-inducible miR-196a modulates glioblastoma cell proliferation and migration through complex regulation of NRAS.
    Takkar S; Sharma V; Ghosh S; Suri A; Sarkar C; Kulshreshtha R
    Cell Oncol (Dordr); 2021 Apr; 44(2):433-451. PubMed ID: 33469841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation.
    Liu YJ; Ma YC; Zhang WJ; Yang ZZ; Liang DS; Wu ZF; Qi XR
    Oncotarget; 2017 Jun; 8(26):42495-42509. PubMed ID: 28477008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non-coding RNA CASP5 promotes the malignant phenotypes of human glioblastoma multiforme.
    Zhou Y; Dai W; Wang H; Pan H; Wang Q
    Biochem Biophys Res Commun; 2018 Jun; 500(4):966-972. PubMed ID: 29715460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
    Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
    Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
    Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
    PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.